治療Vancomycin抗藥性的Enterococcus faecium感染、由Staphylococcus aureus或Streptococcus pneumoniae所引起的醫院感染肺炎、由Streptococcus pneumoniae或Staphylococcus aureus所引起的社區感染的肺炎、複雜性皮膚和皮膚構造感染、非複雜性皮膚和皮膚構造感染。

Antibiotic, Oxazolidinone

Absorption: Rapid and extensive.
Distribution: 0.65 L/kg.
Protein binding: 31%.
Bioavailability: ~100%.
Half-life elimination: 4.9 hours.
Time to peak: 1 to 2 hours.
Excretion: Urine, feces (two metabolites of linezolid may accumulate in patients with severe renal impairment).

Hypersensitivity to linezolid or any component of the formulation; concurrent use or within 2 weeks of MAO inhibitors

C

>10%: diarrhea (8% to 11%), decreased white blood cell count.
1% to 10%: pruritus, skin rash (1% to 2%), Increased amylase (≤2%), increased lactate dehydrogenase (≤2%), abdominal pain (≤2%), dysgeusia (1% to 2%), increased serum lipase, loose stools (2%), nausea (2% to 7%), oral candidiasis (≤2%), vomiting (2% to 9%), vulvovaginal candidiasis (1% to 2%), anemia, decreased neutrophils, decreased platelet count (≤10%), eosinophilia, thrombocytopenia, abnormal hepatic function tests (≤2%), increased serum alanine aminotransferase, increased serum alkaline phosphatase (≤4%), increased serum aspartate aminotransferase (2% to 5%), increased serum bilirubin, fungal infection (≤2%), dizziness (2% to 3%), headache, vertigo, increased blood urea nitrogen (≤2%), increased serum creatinine (≤2%)

Complicated skin and skin tissue infections, community-acquired pneumonia, hospital-acquired pneumonia: 600mg every 12 hours for 10 to 14 days.
Vancomycin-resistant Enterococcus faecium infection: 600mg every 12 hours for 14 to 28 days.
Infections of uncomplicated skin and skin tissue: 400mg every 12 hours for 10 to 14 days.

Children under 11 years old:
Complicated skin and skin tissue infections, community-acquired pneumonia, hospital-acquired pneumonia: 10mg/kg every 8 hours for 10 to 14 days.
Vancomycin-resistant Enterococcus faecium infection: 10mg/kg every 8 hours for 14 to 28 days.
Infections of uncomplicated skin and skin tissue: <5 years: 10mg/kg every 8 hours for 10 to 14 days; 5-11 years: 10mg/kg every 12 hours for 10 to 14 days.

Patients with CrCl <30 mL/minute and an anticipated treatment course >10 days: reducing dose to 300 mg twice daily after 72 hours with therapeutic drug monitoring to reduce the risk of thrombocytopenia.